CardioSignal receives ISO 27001 certification for information security
CardioSignal makes reliable heart disease detection available to smartphone users. An ambitious cybersecurity strategy is crucial to achieve accessibility and trust in new remote care models the company is developing with its customers globally.
ISO/IEC 27001:2013 (ISO 27001), the globally most recognized information security standard, sets the specifications of information security management. For CardioSignal, this certification is an important milestone in demonstrating long commitment and compliance with information security. The CardioSignal mobile application is a class IIa medical device in Europe.
The certification was received in September 2022, with Kiwa Inspecta as the certification body. The certification covers the company’s operations, business processes, development, and the maintenance of CardioSignal technology.
“From the beginning, we have built the CardioSignal technology on a robust scientific foundation and quality management practices. I am extremely proud to see our team recognized for our continued commitment to the privacy and security of our customers. Strong focus on information security has been a key enabler in achieving business growth in the rapidly evolving field of digital health and remote cardiovascular care,” said CEO and cardiologist Juuso Blomster.
The company continues to monitor and develop information security and privacy practices to instill patient safety and confidence in the CardioSignal technology.
"Effective information security is a crucial element of any digital service and especially in the health technology area. So, as an auditor, it has been a pleasure to see how the principles and requirements of the ISO 27001 standard have been truly understood and integrated into organization’s processes – not built as a separate layer on top of them," commented Lead Auditor Jyrki Lahnalahti from Kiwa Inspecta.
Juuso Blomster, CardioSignal Jyrki Lahnalahti, Kiwa Inspecta
Further information
CEO Juuso Blomster, juuso.blomster@cardiosignal.com
Information Security Manager Tomi Järvinen, tomi.jarvinen@cardiosignal.com
Communications Director Juulia Simonen, juulia.simonen@cardiosignal.com
About CardioSignal
We develop groundbreaking solutions for the detection of heart diseases with digital cardiac biomarkers. CardioSignal utilizes motion sensor technology to non-invasively measure cardiac motion and function. Originally an academic spinoff, the company’s patented technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior, a health technology company based in Finland and United States.
About Kiwa Inspecta
Kiwa is an independent global company in Testing, Inspection and Certification (TIC). Kiwa’s core businesses are supported and strengthened by (strictly separated) training, consultancy and data services. With its TIC and adjacent services, Kiwa creates trust in its customers’ products, services, processes, (management) systems and employees. It does so in a wide variety of market segments, ranging from drinking water and (renewable) energy, construction and healthcare to food, feed & farm and medical & pharma. Kiwa has clients in manufacturing and process industries, (business) services, public and private utilities, governments and international institutions. Kiwa employs around 10,000 people in offices in more than 40 countries across Europe, Asia-Pacific, North and Latin America.
